Association between downexpression of miR-1301 and poor prognosis in patients with glioma
Q.-L. Bai, C.-W. Hu, X.-R. Wang, G.-F. Yin, J.-X. Shang Department of Neurosurgery, Cangzhou Central Hospital, Cangzhou, Hebei, China. bqq306b@gmail.com
OBJECTIVE: MiR-1301 has been shown to be frequently down-regulated in various tumors. However, the clinical significance of miR-1301 in human glioma is still unclear. The aim of this study was to evaluate the prognostic impact of the expressions of miR-1301 in patients with glioma.
PATIENTS AND METHODS: Quantitative Real-time PCR was used to determine the expression miR-1301 in glioma tissues and pair-matched adjacent normal tissues. The relationships between miR-1301 expression and clinicopathological parameters were examined by X2 test. Kaplan-Meier curves and multivariate Cox proportional models were used to study the impact on clinical outcome.
RESULTS: We observed that miR-1301 expression was significantly lower in glioma tissues compared with adjacent non-cancerous tissues (p<0.01). Also, low expressions of miR-1301 were significantly associated with high WHO grade (p<0.006), low Karnofsky performance score (KPS) (p=0.001), and large tumor size (p=0.004). Furthermore, the data of Kaplan-Meier survival analysis showed that low miR-1301 expression significantly associated with a worse overall survival (p=0.003) and disease-specific survival (p=0.001). Finally, the univariate and multivariate analysis showed that the miR-1301 expression was an independent predictor for both overall survival and disease-specific survival in glioma.
CONCLUSIONS: Our findings suggested lower miR-1301 expression resulted in poorer survival in patients with glioma, which may provide important indicators for further research.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
Q.-L. Bai, C.-W. Hu, X.-R. Wang, G.-F. Yin, J.-X. Shang
Association between downexpression of miR-1301 and poor prognosis in patients with glioma
Eur Rev Med Pharmacol Sci
Year: 2017
Vol. 21 - N. 19
Pages: 4298-4303